Advanced search
  • Home
  • Responsibility

Responsibility

We are transforming GSK to create a company that creates value for patients, consumers and governments, as well as shareholders. We place great importance on what we achieve but also how we achieve it. We believe business should play a greater role in tackling social, economic and environmental challenges.

We have four core areas of focus which reflect the issues we see as most important for responsible and sustainable business growth.

Health for all
Improving the health and well-being of people around the world

Our people and communities
Developing our people and supporting communities

Our planet
Protecting the natural resources we need for the future

Our behaviour
Being open and honest in everything we do

At GSK, we firmly believe that operating in a responsible and ethical way is essential for the success of our business. We have come a long way but recognise that there is much more we can do and we will continue to challenge ourselves.

CEO Sir Andrew Witty

Corporate responsibility

Corporate responsibility is about what we do and how we do it. It helps us to create the products that people need and value, to operate efficiently, to gain the trust of our stakeholders and to foster the right conditions for the growth of our business.

Health for all

Through investment in R&D, infrastructure and innovative pricing we are working with stakeholders to make our medicines, vaccines and consumer products available to as many people who need them as possible, regardless of where they live or their ability to pay.

Our people and communities

We respect all people. We support employees to reach their full potential and aim to make a positive difference to the communities in which we operate through economic contribution, investment, education programmes and partnerships.

Our behaviour

We are building a strong values-based culture. We recognise that we need to be open about what we do, how we do it and the challenges we face. Our actions are backed by robust policies and strong compliance processes. We expect the same standards from our supplies, contractors and business partners.

Our planet

We are committed to minimising our environmental impact across our value chain and lifecycle of our products by setting ambitious goals to reduce our carbon footprint, water and waste.

2011 CR Report

Download the CR Report (PDF)

Our approach to malaria

We are on the cusp of creating the world’s first malaria vaccine. In 2011, late-stage trials showed that our vaccine candidate reduces the risk of malaria by half in African children aged 5-17 months. We have committed to price the vaccine at a level that covers costs and generates a small return of around 5% that will be ploughed back into malaria research.

Bringing Science to the London 2012 Olympic and Paralympic Games

We are using the excitement generated by the London 2012 Olympic and Paralympic Games as an opportunity to advance scientific progress, inspire a new generation of young scientists and improve the health and well-being of communities and employees.

Changing the way we incentivise our sales teams in the USA

We have de-coupled the pay of our sales representatives in the USA from the number of prescriptions issued, bringing our sales model more in line with our values and customer expectations.

Product carbon footprints

The main contributors to our carbon footprint are from our supply chain and propellant release when our inhaler products are used. We are developing a product carbon footprint approach to help us reduce our impacts further.